entertainment -WSS

entertainment

author：focus 2025-09-30 00:48:17 - browse：7325

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： STAT wants to know your pick for a great summer read or listen

focus

WSS

FDA proposes changes to key medical devices approval pathway

The biotech scorecard for Q3: 15 stock

Vertex cell therapy lets patients with type 1 diabetes stop insulin

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Use doctors trained outside the U.S. to ease the physician shortage

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

focus

entertainment

explore

The cancer drug shortage isn’t new — and neither are the solutions

A letter from the executive editor: The 2023 STATUS List

Dobbs anniversary: the lost opportunity of abortion as health care

IRA could hurt research into orphan drugs for rare diseases

Continuity nursing helped my family in our darkest PICU moments

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Apple is now the first public company to be valued at $3 trillion

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

After affirmative action ruling, medical educators look to 'holistic review'

Acelyrin, a rare IPO success, stumbles in its first big test

explore

WATCH: Why do bright lights make us see spots?

Canadians with cystic fibrosis outlive Americans by a decade

Generate Biomedicines machine learning biotech raises $273M

Long Covid needs a new name — and a new frame

What to make of Biden’s latest efforts on cancer research

What affirmative action's end means to a medical student

leisure time

focus

hotspot

focus